ICO 007

Drug Profile

ICO 007

Alternative Names: ICO-007; ISIS-13650

Latest Information Update: 04 Dec 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer iCo Therapeutics; JDRF
  • Class Antisense oligonucleotides; Eye disorder therapies
  • Mechanism of Action Proto oncogene proteins c raf inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Discontinued Age-related macular degeneration; Diabetic macular oedema

Most Recent Events

  • 28 Nov 2014 ICO 007 is available for licensing as of 28 Nov 2014. www.icotherapeutics.com/
  • 28 Nov 2014 Discontinued - Phase-II for Diabetic macular oedema in USA (Intravitreous)
  • 28 Nov 2014 Discontinued - Preclinical for Age-related macular degeneration in USA (Intravitreous)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top